Rational design of non-resistant targeted cancer therapies
Author:
Publisher
Springer Science and Business Media LLC
Subject
Multidisciplinary
Link
http://www.nature.com/articles/srep46632.pdf
Reference88 articles.
1. Vadlapatla, R. K., Vadlapudi, A. D., Pal, D. & Mitra, A. K. Mechanisms of drug resistance in cancer chemotherapy: coordinated role and regulation of efflux transporters and metabolizing enzymes. Current pharmaceutical design 19, 7126–7140 (2013).
2. Sawyers, C. Targeted cancer therapy. Nature 432, 294–297, doi: 10.1038/nature03095 (2004).
3. Gonzalez-Angulo, A. M., Hortobagyi, G. N. & Ellis, L. M. Targeted therapies: peaking beneath the surface of recent bevacizumab trials. Nature reviews. Clinical oncology 8, 319–320, doi: 10.1038/nrclinonc.2011.66 (2011).
4. Morita, S. et al. Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations. Clin Cancer Res 15, 4493–4498, doi: 10.1158/1078-0432.CCR-09-0391 (2009).
5. Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. The New England journal of medicine 364, 2507–2516, doi: 10.1056/NEJMoa1103782 (2011).
Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Discovery of Novel EGFR Inhibitor Targeting Wild-Type and Mutant Forms of EGFR: In Silico and In Vitro Study;Molecules;2023-03-28
2. Structural dynamics and kinase inhibitory activity of three generations of tyrosine kinase inhibitors against wild-type, L858R/T790M, and L858R/T790M/C797S forms of EGFR;Computers in Biology and Medicine;2022-08
3. Centromere protein N promotes lung adenocarcinoma progression by activating PI3K/AKT signaling pathway;Genes & Genomics;2022-02-12
4. Canine Oncopanel: A capture‐based, NGS platform for evaluating the mutational landscape and detecting putative driver mutations in canine cancers;Veterinary and Comparative Oncology;2021-08-09
5. Identification of Vinyl Sulfone Derivatives as EGFR Tyrosine Kinase Inhibitor: In Vitro and In Silico Studies;Molecules;2021-04-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3